Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25

Journal of Clinical Oncology

Volumn 17, Issue 11, 1999, Pages 3374-3388

  Fisher, Bernard ^a   Anderson, Stewart ^a   DeCillis, Arthur ^a   Dimitrov, Nikolay ^a   Atkins, James N ^a   Fehrenbacher, Louis ^a   Henry, Patrick H ^a   Romond, Edward H ^a   Lanier, Keith S ^a   Davila, Enrique ^a   Kardinal, Carl G ^a   Laufman, Leslie ^a   Pierce, H Irving ^a   Abramson, Neil ^a   Keller, Alan M ^a   Hamm, John T ^a   Wickerham, D L ^a   Begovic, Mirsada ^a   Tan Chiu, Elizabeth ^a   Tian, Wei ^a   Wolmark, Norman ^a   more..

^a NSABP Foundation Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; NEOSTAR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; HEMORRHAGIC CYSTITIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; TREATMENT OUTCOME;

EID: 0032730426     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.11.3374     Document Type: Article

References (36)

1. De Vita VT: Dose-response is alive and well. J Clin Oncol 4:1157-1159, 1986
2. Hryniuk W, Bush H: The importance of dose-intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1288, 1984
3. Hryniuk W: More is better. J Clin Oncol 6:1365-1367, 1988
4. Tannock IF, Boyd NF, DeBoer G, et al: A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6:1377-1387, 1988
5. Hryniuk W, Levine MN, Levin L: Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. NCI Monogr 1:87-94, 1986
6. Hryniuk W, Levine MN: Analysis of dose-intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4:1162-1170, 1986
7. Fisher B, Fisher ER, Redmond C: Ten-year results from the NSABP clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol 4:929-941, 1986
8. Fisher B, Redmond C, Brown A, et al: Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305:1-6, 1981
9. Fisher B, Anderson S, Wickerham DL, et al: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15:1858-1869, 1997
10. Cutler SJ, Ederer F: Maximum utilization of the life table method in analyzing survival. J Chronic Dis 8:699-712, 1958
11. Lewis JA, Machin D: Intention to treat: Who should use ITT? Br J Cancer 68:647-650, 1993
12. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
13. Hankey BF, Myers MH: Evaluating differences in survival between two groups of patients. J Chronic Dis 24:523-531, 1971
14. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc B 135:185-206, 1972
15. Gail M, Simon R: Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 41:361-372, 1985
16. Cox DR: Regression models and life-tables. J R Stat Soc B 30:248-275, 1972
17. Hryniuk WM: Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 14:65-74, 1987
18. Steward WP: High dose chemotherapy with haemopoietic support for breast cancer. Eur J Cancer 31A:S21-S24, 1995 (suppl 7)
19. Triozzi PL, Rhoades C, Thornton DE: High-dose chemotherapy for breast cancer. Cancer Treat Rev 21:185-198, 1995
20. Overgaard M, Hansen PS, Overgaard J, et al: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 337:949-955, 1997
21. Ragaz J, Jackson SM, Le N, et al: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337:956-962, 1997
22. Hellman S: Stopping metastases at their source. N Engl J Med 337:996-997, 1997
23. DeCillis A, Anderson S, Bryant J, et al: Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) on NSABP B-25: An update. Proc Am Soc Clin Oncol 16:130a, 1997 (abstr 459)
24. Rodenhuis S, Richel DJ, van der Wall E, et al: Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 352:515-521, 1998
25. Hortobagyi GN, Buzdar AU, Champlin R, et al: Lack of efficacy of adjuvant high-dose (HD) tandem combination chemotherapy (CT) for high-risk primary breast cancer (HRPBC): A randomized trial. Proc Am Soc Clin Oncol 17:123a, 1998 (abstr 471)
26. Budman DR, Berry DA, Cirrincione CT, et al: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 90:1205-1211, 1998
27. Henderson IC, Hayes DF, Gelman R: Dose-response in the treatment of breast cancer: A critical review. J Clin Oncol 6:1501-1515, 1988
28. Bastholt L, Dalmark M, Gjedde SB, et al: Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 14:1146-1155, 1996
29. Frei E III, Teicher BA, Cucchi CA, et al: Resistance to alkylating agents: Basic studies and therapeutic implications, in Wooley PV III, Tew KD (eds): Mechanisms of Drug Resistance to Neoplastic Cells. Bristol-Myers Cancer Symposium. San Diego, CA, Academic Press, 1988, pp 69-86
30. Frei E III, Antman K, Teicher B, et al: Bone marrow autotransplantation for solid tumors: Prospects. J Clin Oncol 7:515-526, 1989
31. Zujewski J, Nelson A, Abrams J: Much ado about not... enough data: High-dose chemotherapy with autologous stem cell rescue for breast cancer. J Natl Cancer Inst 90:200-209, 1998
32. Peters W, Rosner G, Vredenburgh J, et al: A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc Am Soc Clin Oncol 18:1a. 1999 (abstr 2)
33. b supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy. Proc Am Soc Clin Oncol 18:2a, 1999 (abstr 3)
34. Bezwoda WR: Randomised, controlled trial of high dose chemotherapy (HD-CNVp) versus standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer. Proc Am Soc Clin Oncol 18:2a, 1999 (abstr 4)
35. Norton L: Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 24:S10-3-S10-10, 1997 (suppl 10)
36. Frei E III, Elias A, Wheeler C, et al: The relationship between high-dose treatment and combination chemotherapy: The concept of summation dose intensity. Clin Cancer Res 4:2027-2037, 1998